Enanta v. Pfizer: PAXLOVID Patent Ruled Invalid After 958-Day Fight
Enanta Pharmaceuticals sued Pfizer in June 2022, alleging that PAXLOVID — the blockbuster COVID-19 antiviral — infringed US11358953B2, Enanta’s patent covering protease inhibitor compounds. On February 3, 2025, the Massachusetts District Court granted Pfizer’s motion for summary judgment of invalidity, ending the case after 958 days with a full defense verdict.
Enanta’s PAXLOVID Patent Claim Extinguished at Summary Judgment
On June 21, 2022, Enanta Pharmaceuticals, Inc. filed suit against Pfizer, Inc. in the U.S. District Court for the District of Massachusetts (Case No. 1:22-cv-10967), alleging that Pfizer’s PAXLOVID — a co-packaged combination of nirmatrelvir tablets and ritonavir tablets — infringed Enanta’s U.S. Patent No. 11,358,953 B2, covering protease inhibitor antiviral compounds. PAXLOVID was at the time one of the world’s most commercially significant pharmaceutical products, having received Emergency Use Authorization for COVID-19 treatment.
The case closed on February 3, 2025, when the Court entered final judgment for Pfizer following its grant of Pfizer’s Motion for Summary Judgment of Invalidity (Dkt. 269) via Memorandum and Order (Dkt. 393). The Court found the ‘953 Patent invalid as a matter of law, rendering Enanta’s infringement count moot. Pfizer’s Counterclaim Count II (Declaration of Invalidity) was resolved in Pfizer’s favour, while Counterclaim Count I (Declaration of Noninfringement) was dismissed without prejudice — a procedural housekeeping step consistent with the invalidity ruling mooting the noninfringement question.
The 958-day duration reflects the resource-intensive nature of pharmaceutical patent invalidity litigation, particularly against a blockbuster product. Summary judgment of invalidity — rather than a trial outcome — suggests the Court found the patent’s invalidity sufficiently clear-cut to resolve without full fact-finding, which typically indicates anticipation or obviousness grounds that could not survive scrutiny at the claim-construction or prior-art stage. The precise invalidity grounds articulated in Dkt. 393 are not fully reproduced in the public docket summary, leaving the specific legal basis — whether anticipation, obviousness, or another ground — to be confirmed by reviewing the full memorandum.
Filing to Judgment on the merits for Defendant in 958 days
958 days — above the median for patent cases in D. Mass., reflecting the complexity of pharmaceutical invalidity litigation
Summary judgment for Pfizer: what the invalidity ruling means for both parties
Summary judgment of invalidity: the patent is legally dead
A grant of summary judgment of invalidity means the Court found, viewing facts in the light most favourable to Enanta, that no reasonable jury could have upheld the ‘953 Patent’s validity. This is a high-bar ruling — the Court effectively determined that the patent fails the statutory requirements (e.g., novelty or non-obviousness under 35 U.S.C. §§ 102/103) as a matter of law, without needing a jury trial. The patent cannot be enforced against Pfizer or any other party unless the ruling is overturned on appeal.
Invalidity on the meritsEnanta loses enforcement rights over the ‘953 Patent
Final judgment entered against Enanta means the ‘953 Patent has been adjudicated invalid in this proceeding. Enanta retains the right to appeal to the Federal Circuit, but in the interim — and absent a stay — the patent cannot be enforced. For a company whose pipeline is built on protease inhibitor chemistry, this ruling weakens its IP position in the antiviral space. Any licensing discussions premised on the ‘953 Patent’s validity are materially undermined.
Patent invalidatedPfizer secures PAXLOVID’s freedom to operate via invalidity
Pfizer’s win is structural, not merely procedural. By obtaining a judgment of invalidity rather than non-infringement, Pfizer eliminates the patent as a future threat — not just this claim. The noninfringement counterclaim was dismissed without prejudice, consistent with the invalidity ruling mooting it. Pfizer’s commercial runway for PAXLOVID is cleared of this specific patent obstacle, though other IP challenges in the antiviral space remain possible from other patentees.
Freedom to operate confirmedAntiviral IP landscape: invalidity ruling sets a precedent signal
This outcome suggests that courts scrutinising COVID-era antiviral patents — particularly those covering protease inhibitor scaffolds that share structural proximity with earlier prior art — are willing to resolve invalidity at summary judgment rather than trial. For companies holding or licencing similar antiviral compound patents, this ruling is a material risk signal. Third parties monitoring PAXLOVID-adjacent IP should assess whether their own compound claims could face analogous invalidity arguments.
High invalidity risk for analogous patentsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Enanta Pharmaceuticals, Inc. | Company | Pharmaceutical R&D company — holder of US11358953B2 covering antiviral protease inhibitor compoundsSearch in Eureka ↗ |
| Defendant | Pfizer, Inc. | Company | Global pharmaceutical company; maker of PAXLOVID (nirmatrelvir/ritonavir) COVID-19 antiviral treatmentSearch in Eureka ↗ |
| Plaintiff counsel | Barbara A. Fiacco | Attorney | Counsel for Enanta Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Donald R. Ware | Attorney | Counsel for Enanta Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Younkin | Attorney | Counsel for Enanta Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Stuart Knight | Attorney | Counsel for Enanta Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Taylor R. Davis | Attorney | Counsel for Enanta Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Foley Hoag LLP | Law Firm | Representing Enanta Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Alexander T. Hornat | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Ben Picozzi | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Christopher Yeager | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | David I. Berl | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | David M. Krinsky | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Erik Paul Belt | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Julie Tavares | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Katarina Overberg | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Lee C. Bromberg | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Nicholas Loftus | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Thomas H.L. Selby | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant counsel | Wyley S. Proctor | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Defendant law firm | McCarter & English, LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Defendant law firm | Williams & Connolly LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Massachusetts District CourtSearch in Eureka ↗ |
Official order — verbatim text
The Court’s order is unambiguous in its scope: final judgment entered for Pfizer on both Enanta’s infringement count and Pfizer’s invalidity counterclaim, while the noninfringement counterclaim is dismissed without prejudice as moot. The procedural structure — invalidity granted, noninfringement mooted — is the strongest possible outcome for a defendant, as it extinguishes the patent’s enforceability entirely rather than merely defeating this assertion. The summary judgment standard requires no genuine dispute of material fact, meaning the Court found Enanta’s validity arguments legally insufficient even on the most favourable reading of the evidence. This is analytically distinct from a jury verdict and carries immediate preclusive effect subject to appeal.
US11358953B2 — Antiviral Protease Inhibitor Compounds (Enanta)
U.S. Patent No. 11,358,953 B2 (application number US17/522,176) is held by Enanta Pharmaceuticals and covers antiviral compounds operating as protease inhibitors — a class of molecules designed to block the enzymatic activity required for viral replication. Enanta asserted this patent against Pfizer’s nirmatrelvir, the active antiviral component of PAXLOVID, which is itself a 3CL protease inhibitor targeting SARS-CoV-2. The patent’s issuance reflects Enanta’s longstanding focus on small-molecule antiviral chemistry, particularly in the HCV and coronavirus protease inhibitor space.
The strategic stakes around this patent were amplified by PAXLOVID’s commercial scale — one of the highest-revenue pharmaceutical products of the COVID-19 era. Enanta’s assertion effectively claimed a structural or compositional overlap between its patented compounds and nirmatrelvir. The Court’s invalidity ruling suggests the ‘953 Patent’s claims may have been insufficiently differentiated from prior art in the crowded protease inhibitor field. For competitors and R&D teams working on next-generation antiviral compounds, this case is a cautionary signal about the importance of robust claim differentiation from earlier protease inhibitor scaffolds, including Enanta’s and others’ prior publications.
Should your antiviral pipeline run an FTO against US11358953B2?
Any R&D team or product group developing protease inhibitor-based antiviral compounds — particularly those targeting 3CL or serine proteases in respiratory viruses — should assess their exposure to the Enanta ‘953 Patent family. Despite the invalidity ruling in this case, the patent remains technically in force pending appeal and may still be asserted in other jurisdictions or against other products. Companies commercialising nirmatrelvir analogues, next-generation COVID antivirals, or broad-spectrum protease inhibitor scaffolds face the highest exposure.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map compound structures against the ‘953 Patent’s claim language, identify prior art that informed Pfizer’s invalidity defence, and benchmark your candidate molecules against the full Enanta protease inhibitor portfolio. Eureka can surface related family members, prosecution history flags, and analogous antiviral patents that may pose parallel risks — giving product teams a defensible clearance record before first commercial use.
Run a freedom-to-operate analysis on US11358953B2 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical patent invalidity cases in U.S. District Courts
Cases involving antiviral compound patent assertions and summary judgment invalidity rulings in U.S. district courts, including the District of Massachusetts.
What this case signals for the antiviral pharmaceutical IP landscape
A summary judgment invalidity win against a major COVID-19 patent sends a clear message about the durability of pharmaceutical compound claims in contested litigation.
Summary judgment invalidity is a nuclear outcome — patent holders must pressure-test claims early
Pfizer’s win without trial indicates the Court found the ‘953 Patent’s invalidity beyond reasonable dispute. Patent holders in the antiviral and protease inhibitor space should conduct rigorous prior art landscape analysis before filing suit — a claim that cannot survive summary judgment likely could not have survived a well-funded IPR petition either.
PAXLOVID’s IP perimeter is now cleaner — but the broader antiviral space remains contested
This ruling clears one specific patent obstacle for Pfizer’s PAXLOVID, but the antiviral protease inhibitor space remains IP-dense. Competitors and follow-on developers should monitor the Federal Circuit for any Enanta appeal, and separately audit their own compound portfolios for prior-art exposure before asserting or licencing compound claims.
Enanta v Pfizer — key questions answered
The Massachusetts District Court granted Pfizer’s Motion for Summary Judgment of Invalidity on February 3, 2025, entering final judgment for Pfizer. Enanta’s infringement claim under US11358953B2 was dismissed on the merits. Pfizer’s noninfringement counterclaim was dismissed without prejudice as moot.
Enanta asserted U.S. Patent No. 11,358,953 B2 (application no. US17/522,176), covering antiviral protease inhibitor compounds. Enanta alleged that nirmatrelvir — the active antiviral ingredient in Pfizer’s PAXLOVID (co-packaged with ritonavir) — fell within the scope of its patent claims.
A summary judgment of invalidity means the Court found, as a matter of law, that no genuine dispute existed as to the patent’s invalidity. The ‘953 Patent cannot be enforced against Pfizer or any third party on the basis of this ruling, unless Enanta successfully appeals the decision to the U.S. Court of Appeals for the Federal Circuit.
Yes. With final judgment entered February 3, 2025, Enanta has 30 days to file a notice of appeal to the Federal Circuit (absent any extension). A Federal Circuit appeal would typically take 18–24 months and would review the district court’s invalidity analysis under de novo (legal questions) or clear-error (factual findings) standards.
Pfizer’s Counterclaim Count I (Declaration of Noninfringement) was dismissed without prejudice because the Court’s invalidity ruling rendered it moot — if the patent is invalid, there is no live infringement question to adjudicate. Dismissal without prejudice preserves Pfizer’s ability to raise noninfringement arguments if the invalidity ruling were reversed on appeal.
PatSnap Eureka searches patents and litigation data to answer instantly.